Mounjaro in Derry: tirzepatide patient guide

What are Mounjaro and tirzepatide?

Mounjaro is a brand name for tirzepatide. Tirzepatide acts on GIP and GLP-1 receptors involved in appetite and blood-glucose regulation. For weight management it is used once weekly, together with a reduced-calorie diet and increased physical activity, when a prescriber determines that it is clinically appropriate.

Who might be considered for treatment?

The licensed indication includes adults with obesity, or some adults who are overweight and have at least one weight-related health condition. Body mass index is only one part of an assessment. A prescriber also needs to consider medical history, current medicines, previous approaches, pregnancy plans and whether treatment can be monitored safely.

Meeting a general weight or BMI threshold does not mean that tirzepatide is automatically appropriate. National guidance, licensed indications and local clinical decisions are not interchangeable, and individual circumstances matter.

What should be discussed before treatment?

• Your complete medical history and current medicines
• Previous pancreatitis, gallbladder problems or significant digestive symptoms
• Diabetes treatment, particularly insulin or sulfonylureas
• Pregnancy, breastfeeding, contraception and plans to become pregnant
• Expected benefits, limitations and the role of nutrition and activity
• How side effects, missed doses, monitoring and follow-up will be handled

Common side effects and important warning signs

Common effects include nausea, diarrhoea, vomiting, constipation, abdominal discomfort and reduced appetite. These can contribute to dehydration. The official patient leaflet contains the complete, current list and should be read before use.

Seek urgent medical advice for severe, persistent abdominal pain—particularly if it reaches the back—as this can be a sign of pancreatitis. Serious allergic reactions require emergency help. Contact your clinician promptly about significant or persistent symptoms rather than changing the dose yourself.

Pregnancy and oral contraception

GLP-1 medicines used for weight management should not be used during pregnancy, while trying to become pregnant or during breastfeeding. MHRA advice states that people using oral contraception with tirzepatide should add a barrier method, such as condoms, for four weeks after starting treatment and for four weeks after each dose increase, or discuss a non-oral contraceptive method with a healthcare professional.

Why follow-up matters

Reviews allow the prescriber to assess response, side effects, hydration, relevant measurements and whether treatment remains safe and useful. They are also an opportunity to discuss nutrition, activity and longer-term maintenance. Treatment should not continue simply because it was initially prescribed.

Other weight-management options

Tirzepatide is not the only possible approach. Depending on individual need, a plan may involve nutrition and activity support, behavioural approaches, another licensed medicine, GP or specialist input, or assessment for bariatric surgery. See our Derry guide to Mounjaro, Wegovy, Foundayo and other weight-management options.

Reliable sources and further reading

• Electronic Medicines Compendium: current Mounjaro product information and patient leaflet
• NICE TA1026: Tirzepatide for managing overweight and obesity
• NICE NG246: Overweight and obesity management
• MHRA: GLP-1 medicines, pregnancy and contraception

Prepared as patient information by Sweenys Health at H Sweeny Chemist, Unit 17 Quayside Shopping Centre, Derry. It does not replace the patient leaflet, an individual consultation or urgent medical care.

Learn about our wider pharmacist-led weight-management service →